AbCellera to Present at the UBS Global Biopharma Conference
AbCellera announced that it will participate in the upcoming UBS Global Biopharma Conference scheduled for November 17, 2026.
Stocks · News reference
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Raises Price Target on Jazz Pharmaceuticals to $305 From $296
RBC Capital Markets has increased its price target for Jazz Pharmaceuticals plc, maintaining an 'Outperform' rating on the stock.
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-11-02 AccNo: 0001232524-26-000056 Size: 932 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Jazz Pharmaceuticals announced it will present clinical research data regarding its neuro-oncology portfolio at the 2026 Society for Neuro-Oncology (SNO) annual meeting.
Jefferies & Co. Initiates Coverage on AbCellera Biologics with Buy Rating
Jefferies & Co. has initiated coverage on AbCellera Biologics Inc. with a "Buy" rating and a price target of $21.
Jazz Pharmaceuticals' ZIIHERA Receives Regulatory Approvals for Biliary Tract Cancer
Jazz Pharmaceuticals' drug ZIIHERA (zanidatamab-hrii) has been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for the treatment of eligible biliary tract cancer (BTC) patients.